Sana Biotechnology
SANA
161 hedge funds and large institutions have $252M invested in Sana Biotechnology in 2025 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 41 reducing their positions, and 32 closing their positions.
50% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $712K
32% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 41
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $258M → $252M (-$6.75M)
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
2% less funds holding
Funds holding: 164 → 161 (-3)
4.44% less ownership
Funds ownership: 70.78% → 66.34% (-4.4%)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.14M |
| 2 |
CC
Clearline Capital
New York
|
+$1.15M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$990K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$871K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$783K |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.06M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.4M |
| 3 |
Morgan Stanley
New York
|
-$3.03M |
| 4 |
BCM
Boxer Capital Management
San Diego,
California
|
-$2.52M |
| 5 |
Corient Private Wealth
Miami,
Florida
|
-$2.44M |
SANA Hedge Fund Activity: Q1 2025 in Review
161 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q1 2025, worth a combined $252M — down 2.6% from $258M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of SANA and 29 opened new positions — a net loss of 3 holders — while 41 trimmed existing stakes and 54 added.
The largest buyer was Citadel Advisors, adding an estimated $6.14M. The largest seller was Vanguard Group, cutting an estimated $8.06M.
- 161 institutional investors held Sana Biotechnology (SANA) as of Q1 2025, down from 164 in Q4 2024.
- Funds reported $252M of Sana Biotechnology stock for Q1 2025, down 2.6% quarter-over-quarter.
- 29 funds opened new Sana Biotechnology positions in Q1 2025 and 32 closed out, a net change of -3 holders.
- The largest Sana Biotechnology buyer in Q1 2025 was Citadel Advisors, an estimated $6.14M added.
- The largest Sana Biotechnology seller in Q1 2025 was Vanguard Group, an estimated $8.06M sold.
Based on aggregated 13F filings for Q1 2025.